Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This study is to characterize the effect of Cobicistat based regimens on parameters of renal
function in HIV infected patients with mild to moderate renal impairment, and also, to
assess the safety and tolerability of those regimens in order to generate appropriate dosing

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006518
  •   2015/03/13
  •   2011/05/11
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01363011  (
  •   GS-US-236-0118  (Gilead Sciences)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Acquired Immunodeficiency Syndrome
  •   HIV Infections
  •   B20-B24 -  Human immunodeficiency virus [HIV] disease
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: EVG/COBI/FTC/TDF
  •   Drug: COBI
  •   Drug: ATV
  •   Drug: DRV
  •   Drug: NRTI
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Change from baseline in estimated glomerular filtration rate; time frame: Baseline to Week 24

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Proportion of participants achieving virologic response (HIV-1 RNA < 50 copies/mL); time frame: Weeks 24, 48 and 96
- Long term effect of COBI-containing regimens on renal parameters; time frame: Weeks 24, 48, and 96; Safety data regarding renal parameters will be summarized.
- Incidence of adverse events and graded laboratory abnormalities; time frame: Baseline to Week 96 plus 30 days; All safety data will be summarized by treatment group.
- Plasma pharmacokinetics (PK) parameters of COBI as measured by Cmax, Tmax, Clast, Tlast, Ctau, λz, AUCtau, and T½.; time frame: Baseline, Weeks, 2, 4, and 24; Cmax is defined as the maximum observed concentration of drug in plasma
Tmax is defined as the time of Cmax
Clast is defined as the last observable concentration of drug
Tlast is defined as the time of Clast
Ctau is defined as the observed drug concentration at the end of the dosing interval
λz is defined as the terminal elimination rate constant
AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)
t1/2 is defined as the estimate of the terminal elimination half-life of the drug

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Australia
  •   Austria
  •   Canada
  •   Dominican Republic
  •   Germany
  •   Mexico
  •   Puerto Rico
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2011/05/31
  •   100
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Cohort 1 (Treatment Naïve)

- Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening

- Screening genotype report must show sensitivity to FTC and TDF

- No prior use of any approved or investigational antiretroviral drug for any length of

Cohort 2 (Pharmacoenhancer Switch)

- Subjects must be receiving atazanavir (ATV) 300 mg/ritonavir (RTV) 100 mg plus 2
NRTIs OR darunavir (DRV) 800 mg/RTV 100 mg plus 2 NRTIs for at least 6 months prior
to screening

- Plasma HIV-1 RNA concentrations at undetectable levels in the 6 months preceding the
screening visit and have HIV-1 RNA < 50 copies/mL at screening

- Subjects experiencing intolerance to RTV (as determined by the Investigator)

Cohort 1 and Cohort 2

- The ability to understand and sign a written informed consent form

- Normal ECG

- Mild to Moderate renal function

- Stable renal function

- Hepatic transaminases (AST and ALT) ≤ 5 x the upper limit of the normal range (ULN)

- Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin (subjects with documented
Gilbert's Syndrome or hyperbilirubinemia due to atazanavir therapy may have total
bilirubin up to 5 x upper limit of normal)

- Adequate hematologic function

- Serum amylase ≤ 5 x ULN

- Males and females of childbearing potential must agree to utilize highly effective
contraception methods from screening throughout the duration of study treatment and
for 30 days following the last dose of study drug

- Age ≥ 18 years

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- New AIDS defining condition diagnosed within the 30 days prior to screening

- Receiving drug treatment for Hepatitis C, or anticipated to receive treatment for
Hepatitis C

- Subjects experiencing decompensated cirrhosis

- Females who are breastfeeding

- Positive serum pregnancy test (female of childbearing potential)

- Implanted defibrillator or pacemaker

- Current alcohol or substance use judged by the Investigator to potentially interfere
with subject study compliance

- History of malignancy within the past 5 years or ongoing malignancy other than
cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous
squamous carcinoma

- Active, serious infections (other than HIV 1 infection) requiring parenteral
antibiotic or antifungal therapy within 30 days prior to Baseline

- Receiving ongoing therapy with any of medications contraindicated for use with EVG,
COBI, FTC, TDF, ATV, DRV; or subjects with any known allergies to the excipients of
EVG/COBI/FTC/TDF STR, COBI tablets, atazanavir capsules or darunavir tablets or
contraindicated for the 2 NRTIs as part of the Cohort 2 regimen

- Participation in any other clinical trial without prior approval

- Any other clinical condition or prior therapy that would make the subject unsuitable
for the study or unable to comply with the dosing requirements

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Gilead Sciences
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Gilead Sciences
    • Javier Szwarcberg, MD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Gilead Sciences
    • Javier Szwarcberg, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   1
  •   2014/07/16
* This entry means the parameter is not applicable or has not been set.